Kane Biotech Inc. (CVE:KNE – Get Free Report) dropped 13.3% during trading on Friday . The stock traded as low as C$0.06 and last traded at C$0.07. Approximately 537,300 shares changed hands during trading, an increase of 855% from the average daily volume of 56,261 shares. The stock had previously closed at C$0.08.
Kane Biotech Stock Performance
The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The stock has a market cap of C$9.36 million, a P/E ratio of 1.63 and a beta of 0.52. The firm’s 50 day moving average is C$0.09 and its 200 day moving average is C$0.10.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Further Reading
- Five stocks we like better than Kane Biotech
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Walmart Stock Alert: Big Price Move Expected Soon
- Investing In Preferred Stock vs. Common Stock
- An Acquisition Just Made Dick’s the Most Exciting Stock in Retail
- 5 discounted opportunities for dividend growth investors
- Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
